Education
About Us
Working with TipRanks
Follow Us
Kuros Biosciences Ltd. (CH:KURN)
:KURN
RESEARCH TOOLSreports
Total Valuation
Kuros Biosciences has a market cap or net worth of $967.42M. The enterprise value is CHF430.56M.
Market Cap$967.42M
Enterprise ValueCHF430.56M
Share Statistics
Kuros Biosciences has 38,110,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38,110,370
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kuros Biosciences’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -8.65%.
Return on Equity (ROE)-0.06
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-8.65%
Return on Capital Employed (ROCE)-0.08
Revenue Per Employee619.30K
Profits Per Employee-32.13K
Employee Count122
Asset Turnover0.89
Inventory Turnover1.43
Valuation Ratios
The current PE Ratio of Kuros Biosciences is -213.72. Kuros Biosciences’s PEG ratio is 2.90.
PE Ratio-213.72
PS Ratio0.00
PB Ratio13.52
Price to Fair Value13.52
Price to FCF391.61
Price to Operating Cash Flow252.93
PEG Ratio2.90
Income Statement
In the last 12 months, Kuros Biosciences had revenue of 75.56M and earned -3.72M in profits. Earnings per share was -0.10.
Revenue75.56M
Gross Profit62.03M
Operating Income-5.00M
Pretax Income-3.35M
Net Income-3.72M
EBITDA-561.00K
Earnings Per Share (EPS)-0.10
Cash Flow
In the last 12 months, operating cash flow was -2.42M and capital expenditures -849.00K, giving a free cash flow of -3.26M billion.
Operating Cash Flow-2.42M
Free Cash Flow-3.26M
Free Cash Flow per Share-0.09
Dividends & Yields
Kuros Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.45
52-Week Price Change300.60%
50-Day Moving Average20.62
200-Day Moving Average20.33
Relative Strength Index (RSI)78.20
Average Volume (3m)208.35K
Important Dates
Kuros Biosciences upcoming earnings date is Aug 13, 2025, TBA Not Confirmed.
Last Earnings DateMar 11, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend Date―
Financial Position
Kuros Biosciences as a current ratio of 2.14, with Debt / Equity ratio of 3.05%
Current Ratio2.14
Quick Ratio1.69
Debt to Market Cap0.00
Net Debt to EBITDA27.93
Interest Coverage Ratio-33.52
Taxes
In the past 12 months, Kuros Biosciences has paid 370.00K in taxes.
Income Tax370.00K
Effective Tax Rate-0.11
Enterprise Valuation
Kuros Biosciences EV to EBITDA ratio is -1.39K, with an EV/FCF ratio of 383.89.
EV to Sales10.30
EV to EBITDA-1.39K
EV to Free Cash Flow383.89
EV to Operating Cash Flow247.94
Balance Sheet
Kuros Biosciences has $14.28M in cash and marketable securities with CHF39.04M in debt, giving a net cash position of -$8.71M billion.
Cash & Marketable Securities$14.28M
Total DebtCHF39.04M
Net Cash-$8.71M
Net Cash Per Share-$0.23
Tangible Book Value Per Share$0.65
Margins
Gross margin is 86.29%, with operating margin of -6.61%, and net profit margin of -4.92%.
Gross Margin86.29%
Operating Margin-6.61%
Pretax Margin-4.43%
Net Profit Margin-4.92%
EBITDA Margin-0.74%
EBIT Margin-4.23%
Analyst Forecast
The average price target for Kuros Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast125.11%
EPS Growth Forecast69.27%